FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3169408085> ?p ?o ?g. }

• W3169408085 endingPage "119705" @default.
• W3169408085 startingPage "119705" @default.
• W3169408085 abstract "Bcl-xL is an anti-apoptotic molecule, but its role in the progression and recurrent/ drug-resistant oral squamous cell carcinoma (OSCC) is poorly understood. A total of one hundred twenty-five human OSCC tissue specimens including twenty-nine adjacent normals (AN), sixty-nine primary tumors (PT), twenty-seven recurrent chemoradiation resistance (RCRT) samples, and oral tongue SCC derived cisplatin-resistant (CisR SCC-4/-9) cells were used, for this study. Protein/mRNA expression levels of Bcl-xL and its regulation by ERK1/2, Stat-3, p53, NFκB, AP-1 (components: c-Jun, c-Fos, and Fra-2) molecules, and cell viability were measured by immunohistochemistry, Western blot, RT-PCR, and MTT analysis. Further, the individual and synergistic effects of Fra-2 (siRNA) and nimbolide were tested in CisR SCC-4/-9 cells. Progressive increase of Bcl-xL expression and its transcriptional-deregulation was observed with OSCC progression and resistance. Among all the possible upstream regulators of Bcl-xL, such as ERK1/2, Stat-3, p53, AP-1, and NFκB, the TF AP-1 (r = 0.644, p = 0.0001) showed maximum association with Bcl-xL mRNA expression. Though differential expression of AP-1 components were detected in OSCC specimens, with more striking positive-correction of c-Jun (r = 0.381, p = 0.049), c-Fos (r = 0.139, p = 0.488, ns) and Fra-2 (r = 0.664, p = 0.0001) with Bcl-xL expression observed stronger in RCRT tumor subgroup. Further, knockdown of Fra-2 and the application of plant-based phytochemical nimbolide decreased Bcl-xL expression and induced apoptosis in CisR SCC-4/-9 cells. Collectively, we have demonstrated the role of Bcl-xL and AP-1 (Fra-2), causing OSCC progression and cisplatin resistance. Targeting Bcl-xL upstream pathway along with the application of nimbolide might be beneficial in eliminating drug-resistant OSCC." @default.
• W3169408085 created "2021-06-22" @default.
• W3169408085 creator A5026586222 @default.
• W3169408085 creator A5044411309 @default.
• W3169408085 date "2021-09-01" @default.
• W3169408085 modified "2023-09-29" @default.
• W3169408085 title "Bcl-xL expression and regulation in the progression, recurrence, and cisplatin resistance of oral cancer" @default.
• W3169408085 cites W1812170084 @default.
• W3169408085 cites W1919861831 @default.
• W3169408085 cites W1971183183 @default.
• W3169408085 cites W1974069520 @default.
• W3169408085 cites W1977258127 @default.
• W3169408085 cites W1983833034 @default.
• W3169408085 cites W1993459241 @default.
• W3169408085 cites W1998370121 @default.
• W3169408085 cites W1999375479 @default.
• W3169408085 cites W2012235333 @default.
• W3169408085 cites W2026070762 @default.
• W3169408085 cites W2036411709 @default.
• W3169408085 cites W2037602535 @default.
• W3169408085 cites W2059192510 @default.
• W3169408085 cites W2060044088 @default.
• W3169408085 cites W2062821569 @default.
• W3169408085 cites W2063366104 @default.
• W3169408085 cites W2072319964 @default.
• W3169408085 cites W2074356752 @default.
• W3169408085 cites W2081236313 @default.
• W3169408085 cites W2085523526 @default.
• W3169408085 cites W2116401711 @default.
• W3169408085 cites W2120308617 @default.
• W3169408085 cites W2125424454 @default.
• W3169408085 cites W2130512686 @default.
• W3169408085 cites W2154817642 @default.
• W3169408085 cites W2160582900 @default.
• W3169408085 cites W2281777572 @default.
• W3169408085 cites W2543056808 @default.
• W3169408085 cites W2590330461 @default.
• W3169408085 cites W2613898758 @default.
• W3169408085 cites W2617904586 @default.
• W3169408085 cites W2768353493 @default.
• W3169408085 cites W2889646458 @default.
• W3169408085 cites W2895328436 @default.
• W3169408085 cites W2897204809 @default.
• W3169408085 cites W2898392093 @default.
• W3169408085 cites W2904033762 @default.
• W3169408085 cites W2908681510 @default.
• W3169408085 cites W3002960004 @default.
• W3169408085 cites W3012459430 @default.
• W3169408085 cites W3104397781 @default.
• W3169408085 doi "https://doi.org/10.1016/j.lfs.2021.119705" @default.
• W3169408085 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34111459" @default.
• W3169408085 hasPublicationYear "2021" @default.
• W3169408085 type Work @default.
• W3169408085 sameAs 3169408085 @default.
• W3169408085 citedByCount "25" @default.
• W3169408085 countsByYear W31694080852021 @default.
• W3169408085 countsByYear W31694080852022 @default.
• W3169408085 countsByYear W31694080852023 @default.
• W3169408085 crossrefType "journal-article" @default.
• W3169408085 hasAuthorship W3169408085A5026586222 @default.
• W3169408085 hasAuthorship W3169408085A5044411309 @default.
• W3169408085 hasConcept C104317684 @default.
• W3169408085 hasConcept C105580179 @default.
• W3169408085 hasConcept C121608353 @default.
• W3169408085 hasConcept C126322002 @default.
• W3169408085 hasConcept C153911025 @default.
• W3169408085 hasConcept C173396325 @default.
• W3169408085 hasConcept C190283241 @default.
• W3169408085 hasConcept C203014093 @default.
• W3169408085 hasConcept C204232928 @default.
• W3169408085 hasConcept C2776415932 @default.
• W3169408085 hasConcept C2776694085 @default.
• W3169408085 hasConcept C2776789625 @default.
• W3169408085 hasConcept C2778239845 @default.
• W3169408085 hasConcept C2779256057 @default.
• W3169408085 hasConcept C31573885 @default.
• W3169408085 hasConcept C502942594 @default.
• W3169408085 hasConcept C53227056 @default.
• W3169408085 hasConcept C55493867 @default.
• W3169408085 hasConcept C71924100 @default.
• W3169408085 hasConcept C86803240 @default.
• W3169408085 hasConceptScore W3169408085C104317684 @default.
• W3169408085 hasConceptScore W3169408085C105580179 @default.
• W3169408085 hasConceptScore W3169408085C121608353 @default.
• W3169408085 hasConceptScore W3169408085C126322002 @default.
• W3169408085 hasConceptScore W3169408085C153911025 @default.
• W3169408085 hasConceptScore W3169408085C173396325 @default.
• W3169408085 hasConceptScore W3169408085C190283241 @default.
• W3169408085 hasConceptScore W3169408085C203014093 @default.
• W3169408085 hasConceptScore W3169408085C204232928 @default.
• W3169408085 hasConceptScore W3169408085C2776415932 @default.
• W3169408085 hasConceptScore W3169408085C2776694085 @default.
• W3169408085 hasConceptScore W3169408085C2776789625 @default.
• W3169408085 hasConceptScore W3169408085C2778239845 @default.
• W3169408085 hasConceptScore W3169408085C2779256057 @default.
• W3169408085 hasConceptScore W3169408085C31573885 @default.
• W3169408085 hasConceptScore W3169408085C502942594 @default.
• W3169408085 hasConceptScore W3169408085C53227056 @default.

• next